Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 4/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24251583 | 0.92 | PDE10A (0.44) | TAS1R3TAS1R1TAS1R2PDE10A | |
| SCHEMBL24251374 | 0.88 | TAS1R3 (0.49) | TAS1R3TAS1R1TAS1R2PDE10AMEN1 | |
| SCHEMBL24251543 | 0.86 | PDE10A (0.45) | TAS1R3TAS1R1TAS1R2PDE10AMEN1 | |
| SCHEMBL24251390 | 0.85 | PDE10A (0.43) | TAS1R3TAS1R1TAS1R2PDE10A | |
| SCHEMBL24251580 | 0.84 | PDE10A (0.41) | TAS1R3TAS1R1TAS1R2PDE10A | |
| SCHEMBL24251504 | 0.84 | PDE10A (0.37) | TAS1R3TAS1R1TAS1R2PDE10AMEN1 | |
| SCHEMBL24251440 | 0.83 | PDE10A (0.39) | TAS1R3TAS1R1TAS1R2PDE10A | |
| SCHEMBL24251396 | 0.82 | TAS1R3 (0.48) | TAS1R3TAS1R1TAS1R2PDE10AMEN1 | |
| SCHEMBL24251512 | 0.81 | TAS1R3 (0.43) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL24251524 | 0.81 | TAS1R3 (0.36) | TAS1R3TAS1R1TAS1R2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | SDHA, PAH, PIGS | TAS1R3 4103/4885TAS1R1 3604/4885TAS1R2 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.